26 March 2020
Due to the COVID-19 pandemic and potential impact of the impending flu season, Lumos Diagnostics, a Planet Innovation company, is working with the Victorian Government to demonstrate the benefits and impact that the FebriDx® test may deliver as an acute respiratory infection (ARI) patient triage tool in the Australian healthcare system.
Any GPs, emergency departments, aged care facilities or other healthcare professionals interested in participating in this free pilot should register their interest on this FebriDx pilot webpage.
FebriDx is a TGA-approved and CE-marked 10-minute point-of-care fingerstick test that helps differentiate viral infections that may necessitate isolation, from bacterial infections that require antibiotic therapy.
By enabling a rapid diagnostic triage at the initial visit or screening stage, the FebriDx test can assist health professionals with decision-making and may thereby help:
The test works by simultaneously detecting Myxovirus resistance protein A (MxA) and C-reactive protein (CRP) directly from peripheral whole blood. MxA is an intracellular protein that becomes elevated in the presence of acute viral infection and CRP is an acute-phase inflammatory protein that is elevated in the presence of clinically significant infection.
Clinical performance from two prospective multi-center US clinical trials demonstrate the FebriDx test’s high accuracy and 97-99% negative predictive value to exclude a bacterial infection.1,2
In a United Kingdom outcome study, FebriDx was shown to alter clinical management decisions in 48% of patients tested and reduced unnecessary antibiotic prescriptions by 80%3.